Oncotarget

Clinical Research Papers:

Clinical significance of cripto-1 expression in lung adenocarcinoma

Hua Zhang, Bin Zhang, Liuwei Gao, Lianmin Zhang, Kaikai Zhu, Runfen Cheng and Changli Wang _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:79087-79098. https://doi.org/10.18632/oncotarget.15761

Metrics: PDF 1027 views  |   HTML 1520 views  |   ?  


Abstract

Hua Zhang1,2,3,4,*, Bin Zhang1,2,3,4,*, Liuwei Gao1,2,3,4,*, Lianmin Zhang1,2,3,4, Kaikai Zhu2,3,5, Runfen Cheng2,3,5 and Changli Wang1,2,3,4

1 Department of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

2 National Clinical Research Center for Cancer, Tianjin, China

3 Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

4 Tianjin Lung Cancer Center, Tianjin, China

5 Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

* These authors have contributed equally to this work

Correspondence to:

Changli Wang, email:

Keywords: Cripto-1, immunohistochemistry, lung adenocarcinoma, epidermal growth factor receptor, prognosis

Received: June 29, 2016 Accepted: February 20, 2017 Published: February 27, 2017

Abstract

Cripto-1 can promote tumourigenesis and may be a potential prognostic biomarker in several malignancies, yet little is known about this protein in lung adenocarcinoma (LAC). The aim of this study was to evaluate the prognostic value of cripto-1 expression in a cohort of patients with LAC. Tumours from 290 patients with pathologically confirmed LAC were used for an immunohistochemical analysis of cripto-1 expression. The correlation between cripto-1 expression and the clinicopathological parameters of patients, EGFR-TKI sensitivity was analysed. Significant associations between cripto-1 expression and pT status, pN status, pTNM status, E-cadherin expression and EGFR-TKI sensitivity were identified. Compared with patients with low cripto-1 expression, patients with high cripto-1 expression exhibited significantly poorer progression-free survival (PFS) and overall survival (OS). Moreover, multivariate analyses showed that high cripto-1 expression was an independent predictor of worse survival of patients with LAC. The combination of cripto-1 expression and serum CEA level was correlated with both PFS and OS. In conclusion, cripto-1 may be a potential prognostic biomarker of survival in patients with LAC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15761